Literature DB >> 18627218

Enhancement of HIV infection by cellulose sulfate.

Wang Tao1, Chris Richards, Dean Hamer.   

Abstract

Cellulose sulfate, a polyanionic compound derived from cotton, has been proposed as a topical microbicide to reduce the sexual transmission of HIV. However, a phase III clinical trial of a vaginal gel formulation of cellulose sulfate (Ushercell) had to be prematurely closed after early data indicated microbicide users had a higher rate of HIV infection than women using a placebo. The unexpected results of the cellulose sulfate trail prompted us to reexamine and attempt to replicate the available preclinical data for this compound and other polyanions. We show here that cellulose sulfate has a biphasic effect on HIV infection in vitro: at high concentrations it inhibits infection but at low concentrations it significantly and reproducibly increases HIV infection. This stimulatory effect is evident for the R5-tropic strains of virus responsible for sexual transmission, reflects the rate of infection rather than viral growth, and occurs at clinically relevant concentrations of the compound. An examination of published studies shows that the biphasic effect of cellulose sulfate was evident in previous research by independent laboratories and is also found for other polyanions such as dextrin sulfate and PRO2000. These data help in understanding the failure of the Ushercell clinical trial and indicate that cellulose sulfate is not safe for mucosal application in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18627218      PMCID: PMC2927036          DOI: 10.1089/aid.2008.0043

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  26 in total

Review 1.  Antibody-mediated enhancement of viral disease.

Authors:  N J Sullivan
Journal:  Curr Top Microbiol Immunol       Date:  2001       Impact factor: 4.291

2.  Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120.

Authors:  M Moulard; H Lortat-Jacob; I Mondor; G Roca; R Wyatt; J Sodroski; L Zhao; W Olson; P D Kwong; Q J Sattentau
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.

Authors:  E S Daar; X L Li; T Moudgil; D D Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

4.  Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent.

Authors:  Robert A Anderson; Kenneth A Feathergill; Xaio-Hui Diao; Morris D Cooper; Risa Kirkpatrick; Betsy C Herold; Gustavo F Doncel; Calvin J Chany; Donald P Waller; William F Rencher; Lourens J D Zaneveld
Journal:  J Androl       Date:  2002 May-Jun

5.  Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction.

Authors:  Christophe Guillon; Martin Schutten; Patrick H M Boers; Rob A Gruters; Albert D M E Osterhaus
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy.

Authors:  Antonio Valentin; Margherita Rosati; Daniel J Patenaude; Angelos Hatzakis; Leondios G Kostrikis; Marios Lazanas; Kathleen M Wyvill; Robert Yarchoan; George N Pavlakis
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

7.  Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection.

Authors:  Yi-Jun Zhang; Theodora Hatziioannou; Trinity Zang; Douglas Braaten; Jeremy Luban; Stephen P Goff; Paul D Bieniasz
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

8.  Single and multiple exposure tolerance study of cellulose sulfate gel: a Phase I safety and colposcopy study.

Authors:  C Mauck; D H Weiner; S Ballagh; M Creinin; D F Archer; J Schwartz; H Pymar; J J Lai; M Callahan
Journal:  Contraception       Date:  2001-12       Impact factor: 3.375

9.  Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection.

Authors:  C Flexner; P A Barditch-Crovo; D M Kornhauser; H Farzadegan; L J Nerhood; R E Chaisson; K M Bell; K J Lorentsen; C W Hendrix; B G Petty
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

10.  A potent anti-HIV immunotoxin blocks spreading infection by primary HIV type 1 isolates in multiple cell types.

Authors:  Kira K Lueders; Stephen C De Rosa; Antonio Valentin; George N Pavlakis; Mario Roederer; Dean H Hamer
Journal:  AIDS Res Hum Retroviruses       Date:  2004-02       Impact factor: 1.723

View more
  35 in total

Review 1.  Vaginal drug delivery systems for HIV prevention.

Authors:  Lisa Cencia Rohan; Alexandra B Sassi
Journal:  AAPS J       Date:  2009-02-05       Impact factor: 4.009

2.  Transport theory for HIV diffusion through in vivo distributions of topical microbicide gels.

Authors:  Bonnie E Lai; Marcus H Henderson; Jennifer J Peters; David K Walmer; David F Katz
Journal:  Biophys J       Date:  2009-11-04       Impact factor: 4.033

Review 3.  Development of topical microbicides to prevent the sexual transmission of HIV.

Authors:  Robert W Buckheit; Karen M Watson; Kathleen M Morrow; Anthony S Ham
Journal:  Antiviral Res       Date:  2009-10-27       Impact factor: 5.970

4.  Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.

Authors:  Philippe Selhorst; Ana C Vazquez; Katty Terrazas-Aranda; Johan Michiels; Katleen Vereecken; Leo Heyndrickx; Jan Weber; Miguel E Quiñones-Mateu; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

5.  Evaluation of WLBU2 peptide and 3-O-octyl-sn-glycerol lipid as active ingredients for a topical microbicide formulation targeting Chlamydia trachomatis.

Authors:  M C Skinner; A O Kiselev; C E Isaacs; T A Mietzner; R C Montelaro; M F Lampe
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

6.  A styrene-alt-maleic acid copolymer is an effective inhibitor of R5 and X4 human immunodeficiency virus type 1 infection.

Authors:  Vanessa Pirrone; Shendra Passic; Brian Wigdahl; Robert F Rando; Mohamed Labib; Fred C Krebs
Journal:  J Biomed Biotechnol       Date:  2010-05-31

7.  Structure activity relationship of dendrimer microbicides with dual action antiviral activity.

Authors:  David Tyssen; Scott A Henderson; Adam Johnson; Jasminka Sterjovski; Katie Moore; Jennifer La; Mark Zanin; Secondo Sonza; Peter Karellas; Michael P Giannis; Guy Krippner; Steve Wesselingh; Tom McCarthy; Paul R Gorry; Paul A Ramsland; Richard Cone; Jeremy R A Paull; Gareth R Lewis; Gilda Tachedjian
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

8.  Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells.

Authors:  M Juliana McElrath; Lamar Ballweber; Andrew Terker; Allison Kreger; Polachai Sakchalathorn; Barry Robinson; Michael Fialkow; Gretchen Lentz; Florian Hladik
Journal:  Antimicrob Agents Chemother       Date:  2009-11-30       Impact factor: 5.191

9.  Packaging limits and stability of HIV-1 sequences in a coxsackievirus B vector.

Authors:  John P Miller; Yongzhi Geng; Hwee L Ng; Otto O Yang; Paul Krogstad
Journal:  Vaccine       Date:  2009-05-03       Impact factor: 3.641

10.  Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials.

Authors:  Marla J Keller; Pedro M M Mesquita; N Merna Torres; Sylvia Cho; Gail Shust; Rebecca P Madan; Hillel W Cohen; Julie Petrie; Tara Ford; Lydia Soto-Torres; Albert T Profy; Betsy C Herold
Journal:  PLoS One       Date:  2010-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.